Abstract 3948: Identification of a new therapeutic target in prostate cancer from siRNA screening in Docetaxel-resistant cells

Conclusion: We identified a new chaperone harbouring an enzymatic activity which could be a relevant therapeutic target in chemoresistant CRPC. We are now focusing on the identification of a specific inhibitor in order to validate the role of this target in two Docetaxel-resistant prostate cancer mice models established within the laboratory.Citation Format: Marine Garrido, Nicolas J-p Martin, Catherine Gaudin, Elaine Del Nery, Jacques Camonis, Franck Perez, Stéphanie Lerondel, Alain Le Pape, Karim Fizazi, Anne Chauchereau. Identification of a new therapeutic target in prostate cancer from siRNA screening in Docetaxel-resistant cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3948. doi:10.1158/1538-7445.AM2015-3948

Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Garrido, M., Martin, N. J.-p., Gaudin, C., Del Nery, E., Camonis, J., Perez, F., Lerondel, S., Le Pape, A., Fizazi, K., Chauchereau, A. Tags: Molecular and Cellular Biology Source Type: research